


1-Indol-2-yl-propan-2-ones as dual inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase

Zahov, S., Drews, A., Schulze Elfringhoff, A., Lehr, M.
Institute of Pharmaceutical and Medicinal Chemistry, University of Münster
Hittorfstr. 58-62, D-48149 Münster

Introduction


In mammalian organism, derivatives of arachidonic acid play important roles as algescic and pro-inflammatory as well as analgesic and anti-inflammatory mediators. On the one hand, oxidation products of arachidonic acid such as prostaglandin E₂ and leukotriene B₄ formed via the arachidonic acid cascade are involved in the pathophysiology of pain and inflammation. On the other hand, the arachidonic acid amide anandamide generated via the endocannabinoid pathway has analgetic and anti-inflammatory properties. The key enzyme in the formation of oxidized derivatives of arachidonic acid is cytosolic phospholipase A₂α (cPLA₂α). An important enzyme in the endocannabinoid metabolism is fatty acid amide hydrolase (FAAH), which rapidly inactivates anandamide by cleavage to arachidonic acid and ethanolamine. Therefore, inhibitors of both cPLA₂α and FAAH may represent new agents against pain and inflammation.

Recently we have found that the indole-5-carboxylic acid derivative **1** is a dual inhibitor of cPLA₂α and FAAH. In course of structure-activity relationship studies, the indole part of the molecule has been varied.^[1] In further studies we replaced the octyl chain of **1** by other residues such as alkyloxy, phenoxy, benzyloxy and phenyl. The results of these structural variations of **1** on inhibitory potency against both enzymes are presented.



Synthesis

Most of the target compounds were synthesized on the route outlined below for the formation of **2d**.^[2] In some cases instead of an allyl ester a benzyl ester protecting group was applied. This reaction sequence was less favourable, since cleavage of the benzyl ester in the last reaction step by catalytic hydrogenation led to the formation of indoline by-products.



a: Allylbromide, NaHCO₃, DMF, room temp.; **b:** epichlorohydrin, KOH, Bu₄NBr, room temp.; **c:** 4-(4-fluorophenoxy)phenol, 4-dimethylaminopyridine, 90°C; **d:** Dess-Martin-periodinane reagent, CH₂Cl₂, room temp.; **e:** Pd(PPh₃)₄, CH₃COOH, THF, room temp.

Biochemical Testing

The compounds were screened in a cPLA₂α assay (n=2)^[3] and a FAAH assay (n=2)^[4] as previously described.

Results and Discussion

Table 1: Inhibitory activity of phenyl-, alkyloxy-, phenoxy-, benzyloxy-substituted compounds














R	Comp.	IC ₅₀ [μM] Inhib. cPLA ₂ α	IC ₅₀ [μM] Inhib. FAAH	R	Comp.	IC ₅₀ [μM] Inhib. cPLA ₂ α	IC ₅₀ [μM] Inhib. FAAH
	2a	0.064	0.46	H ₁₃ C ₆ O-	3a	0.034	3.5
	2b	0.027	0.53	H ₁₅ C ₇ O-	3b	0.032	3.4
	2c	0.019	0.23	H ₁₇ C ₈ O-	3c	0.026	2.2
	2d	0.037	0.24	H ₁₉ C ₉ O-	3d	0.023	1.8
	2e	0.041	0.25		3e	0.036	1.3
	2f	0.090	0.53		3f	0.019	>10
	2g	0.040	0.58		3g	0.054	1.9
	2h	n. a.	0.64		3h	0.047	2.9
	2i	0.035	5.9				

Table 2: Inhibitory activity of 2-substituted biaryl compounds

R	Comp.	IC ₅₀ [μM] Inhib. cPLA ₂ α	IC ₅₀ [μM] Inhib. FAAH	R	Comp.	IC ₅₀ [μM] Inhib. cPLA ₂ α	IC ₅₀ [μM] Inhib. FAAH
F-	4a	0.23	0.59	H ₃ C-	4c	3.7	> 10
Cl-	4b	2.8	5.0	H ₃ CO-	4d	8.1	7.4
				H ₃ COOC-	4e	n. a.	> 10

Substitution of the octyl-chain of the lead **1** by a phenyl residue led to a two-fold decrease of cPLA₂α inhibition, while FAAH inhibitory potency increased about six-fold. The IC₅₀-values of obtained **2a** against the two enzymes were 0.064 μM and 0.43 μM, respectively. Introduction of substituents in the phenyl residues of **2a** modified activity as shown in Tables 1 and 2. Replacement of the octyl-group of **1** by different alkyloxy-, phenoxy- and benzyloxy-moieties did not improve cPLA₂α and FAAH inhibition substantially.

References

- [1] Forster, L.; Ludwig, J.; Kaptur, M.; Bovens, S.; Schulze Elfringhoff, A.; Holtfrerich, A.; Lehr, M. *Bioorg. Med. Chem.* **2010**, *18*, 945-952
- [2] Drews, A. *PhD Thesis, University of Münster*, **2008**
- [3] Schmitt, M.; Lehr, M. *J. Pharm. Biomed. Anal.* **2004**, *35*, 135-142
- [4] Forster, L.; Schulze Elfringhoff, A.; Lehr, M. *Anal. Bioanal. Chem.* **2009**, *394*, 1679-1685